TNFSF10 and non-small cell lung carcinoma: The fact that bortezomib has the capacity to enhance rhTRAIL-induced apoptosis in NSCLC cells via multiple mechanisms strongly supports further exploration of bortezomib and TRAIL combinations as promising treatment modalities for NSCLC, warranting additional in vivo studies, which should also be performed with either a pegylated or liposomal formulation, which were beyond the scope of this study.